Incyte Lifts Full-Year 2026 Sales Guidance Following Third-Quarter Loss
Incyte raised its full-year 2026 sales guidance to between $5,210 million and $5,300 million despite booking a $784.8 million loss in the third quarter.
Incyte Corporation updated its outlook after posting its third-quarter financial figures for 2026. The biopharmaceutical company raised its full-year 2026 net sales target to between US$5,210 million and US$5,300 million, surpassing its previous guidance range of $5.13 billion to $5.26 billion.
The updated forecast accompanied a third-quarter net loss of US$784.8 million on revenue of US$1,557.2 million. For the opening nine months of 2026, Incyte generated US$4,503.92 million in revenue, while total net income contracted to US$104.13 million. The reduced profit base reflects higher research, development, and administrative expenditures alongside one-off costs, including an in-process research and development charge tied to its purchase of Vega Therapeutics.
Pipeline developments also advanced during the quarter. Incyte unveiled Phase 1 trial results at ESMO 2026 showing high objective response rates for INCB161734 drug combinations in patients with metastatic colorectal and pancreatic cancers. Additionally, Atebrioz, which was developed by Incyte and licensed to Mirum Pharmaceuticals, obtained FDA approval in September for fibrodysplasia ossificans progressiva.
Commercial momentum has been supported by core brands Jakafi and Opzelura, in addition to newer offerings such as Niktimvo, Monjuvi, and Zynyz. Management previously reported that second-quarter Jakafi sales advanced 7% to $817 million, while revenue outside of Jakafi surged 127% to $671 million. That earlier performance was aided by an agreement with the Centers for Medicare & Medicaid Services concerning Opzelura rebates, an outcome estimated to deliver a $300 million to $310 million net sales boost in 2026.
The company aims to expand its portfolio beyond its primary therapy, targeting between $3 billion and $4 billion in net product sales outside of Jakafi by 2030. Incyte stock had gained 31.4% during the twelve months leading up to October 23, 2026, closing at a level that outpaced the 15.1% return recorded by the S&P 500 over the same stretch.